VITILIGINE: dagli antiossidanti alla Cytokine Theraphy 26 Maggio 2018

Torello Lotti Professor and Chairman of Dermatology and Venereology University of Rome "Guglielmo Marconi", Rome, Italy www.torellolotti.it







Università degli Studi Guglielmo Marconi

professor@torellolotti.it

3286214588

DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY at 2017

- - President World Health Academy Publishing House, Zurich, CH
- - Editor, Dermatologic Therapy, Wiley-Blackwell
- Chief Medical Officer, BIOSKIN EVOLUTION[®]
- Consultant, EVLaser
- - Consultant, GLG, USA
- - Consultant, Advance Medical, USA
- Consultant GUNA International, Italy & USA
- Scientific Director, Dolce Aqua[®], Italy
- Consultant, CLINUVEL , Australia
- - Chief Medical Officer, Applied Biology, Inc , Irvine, CA , USA
- - Executive, Vitiligo Research Foundation, USA
- - Editor in Chief, Journal of Pigmentary Disorders, 2014
- - Consultant, Frankl Pharma Global Ltd- UK 2015
- - Consultant, Cell Vital Co. Munich, Germany 2016

Vitiligo or Vitiligos ? Need for molecular diagnosis and personalized treatment














Vitiligo is a systemic disease.

Lotti T, D'Erme AM.

Clin Dermatol. 2014 May-Jun;32(3):430-4. doi: 10.1016/j.clindermatol.2013.11.01 1

Vitiligo needs systemic treatment because it IS a systemic disease



TITLE

High prevalence of circulating autoantibodies against thyroid hormones in vitiligo and correlation with clinical and historical parameters of patients.

Colucci R, Lotti F, Dragoni F, Arunachalam M, Lotti T.


Br J Dermatol. 2014 Oct: 171(4):786-98


ABSTRACT

Overall 77 of 79 patients (97%) had at least one type of THAb (11 T3-Ab, 10 T4-Ab, 56 both). In the control group, only one person (1%) had THAbs. In patients with vitiligo, T3-Abs were significantly associated with leucotrichia (IgM+IgG, P = 0.033; IgG, P =0.039; IgM, P = 0.005) and thyroglobulin autoantibodies (IgM+IgG, P = 0.031; IgG, P =0.058), while the absence of T3-Ab was related to personal history of cancer (IgM+IgG, P = 0.021; IgG, P = 0.039). T4-Abs were significantly associated with vitiligo activity (IgM+IgG, P < 0.001; IgM, P =(0.037) and duration (IgG, P = 0.013).

Autoimmune Progression







Vitiligo in Children: What's New in Treatment?

Review article

Gianfaldoni S, et al. Open Access Maced J Med Sci. 2018.

Authors

Gianfaldoni S¹, Tchernev G^{2,3}, Wollina U⁴, Lotti J⁵, Rovesti M⁶, Satolli F⁶, França K⁷, Lotti T¹.

Author information

- 1 University G. Marconi of Rome, Dermatology and Venereology, Rome, Italy.
- 2 Medical Institute of Ministry of Interior Department of General, Vascular and Abdominal Surgery, Sofia, Bulgaria.
- 3 Onkoderma Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria.
- 4 Städtisches Klinikum Dresden, Department of Dermatology and Allergology, 01067 Dresden, Germany.
- 5 University G. Marconi of Rome Dept. of Nuclear, Subnuclear and Radiation Physics, Rome, Italy.
- 6 Department of Dermatology, University of Parma, Parma, Italy.
- 7 University of Miami School of Medicine, Miami, Florida, United States and Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.

Citation

Open Access Maced J Med Sci. 2018 Jan 21;6(1):221-225. doi: 10.3889/oamjms.2018.060. eCollection 2018 Jan 25.

Abstract

Vitiligo is an acquired chronic hypopigmentary disorder, which usually stars in childhood. The Authors discuss a short review of the more innovative therapies for childhood vitiligo.

PMID: 29484028 [] PMCID: PMC5816304

Vitiligo in Children: A Review of Conventional Treatments.

Review article

Gianfaldoni S, et al. Open Access Maced J Med Sci. 2018.

Authors

Gianfaldoni S¹, Wollina U², Tchernev G³, Lotti J⁴, França K⁵, Lotti T¹.

Author information

- 1 University G. Marconi of Rome, Dermatology and Venereology, Rome, Italy.
- 2 Städtisches Klinikum Dresden, Department of Dermatology and Allergology, 01067 Dresden, Germany.
- 3 Medical Institute of Ministry of Interior Department of General, Vascular and Abdominal Surgery, Sofia, Bulgaria.
- 4 University G. Marconi of Rome Dept. of Nuclear, Subnuclear and Radiation Physics, Rome, Italy.
- 5 University of Miami School of Medicine Ringgold standard institution, Miami, Florida, United States and Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy.

Citation

Open Access Maced J Med Sci. 2018 Jan 21;6(1):213-217. doi: 10.3889/oamjms.2018.054. eCollection 2018 Jan 25.

Abstract


Vitiligo is an important skin disease of childhood, which may lead to deep psychological trauma, resulting in a poor quality of life and low self-esteem. The Authors discuss a short review of the more conventional therapies available for the treatment of vitiligo in children.

PMID: 29484026 [] PMCID: PMC5816302

- Melanocytes migration -


Melanocytes precursors, knew as melanoblasts, are formed in the the neural crest: in the 11th week of fetal life, they migrate to various sites, where they proliferate and then differentiate into mature melanocyte.

Melanocytes reside in:



Locations and functions of melanocytes

EYE



Vitiligo in Children: A Better Understanding of the Disease.

Review article

Gianfaldoni S, et al. Open Access Maced J Med Sci. 2018.

Authors

Gianfaldoni S¹, Tchernev G^{2,3}, Wollina U⁴, Lotti J⁵, Satolli F⁶, França K⁷, Rovesti M⁶, Lotti T¹.

Author information

- 1 University G. Marconi of Rome, Dermatology and Venereology, Rome 00192, Italy.
- 2 Medical Institute of the Ministry of Interior, Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
- 3 Onkoderma, Private Clinic for Dermatologic Surgery, Sofia, Bulgaria.
- 4 Städtisches Klinikum Dresden Department of Dermatology and Allergology, Dresden, Sachsen, Germany.
- 5 University G. Marconi of Rome, Dept. of Nuclear, Subnuclear and Radiation Physics, Via Plinio 44, Rome 00193, Italy.
- 6 Department of Dermatology, University of Parma, Via Gramsci 14, Parma, Parma 43126, Italy.
- 7 University of Miami School of Medicine, 1400 NW 10th Avenue, Miami, Florida 33136-1015, United States.

Citation

Open Access Maced J Med Sci. 2018 Jan 20;6(1):181-184. doi: 10.3889/oamjms.2018.040. eCollection 2018 Jan 25.

Abstract

Vitiligo is an important skin disease of childhood. The authors briefly discuss the etiopathobiology, clinics and comorbidities of the disease.

PMID: 29484022 [] PMCID: PMC5816297

Metabolic syndrome in vitiligo.

Pietrzak A, et al. Dermatol Ther. 2012 Nov-Dec. Show full citation

Abstract

Vitiligo is an acquired, depigmenting skin disease with still unclear, multifactorial etiopathogenesis. However, there is growing evidence that vitiligo affects not only the skin but it may also be connected with metabolic abnormalities, including glucose intolerance and lipid abnormalities, all of which confirms the systemic nature of the disease. Recently, it has been shown that melanocytes, especially those found in the adipose tissue, due to their ability to decrease inflammation and oxidative damage, are capable of preventing the metabolic syndrome. The article presents updated knowledge on potential metabolic disturbances in vitiligo.

PMID: 23237037 [Indexed for MEDLINE]

Vitiligo: correct pragmatic approach

- Repigmentation first
- Stop progression spreading
- Avoid recurrencies
- Support Patients
- Educate Patients and Scientific Community

Systemic treatment for Vitiligo 2016 – 2018

- JAK Inhibitors
- EdnrB Wnt Signaling
- CD20 Mab
- Afamelanotide
- Statins
- Minocycline
- Low Dose Cytokines and Growth Factors

Systemic treatment for Vitiligo 2016 – 2018

- JAK Inhibitors
- EdnrB Wnt Signaling
- CD20 Mab
- Afamelanotide
- Statins
- Minocycline
- Low Dose Cytokines and Growth Factors

- Janus kinase inhibitors, also known as
- **JAK inhibitors** or **jakinibs**, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway. These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis

 JAK Inhibitors – Janus kinases inhibitors


• TOFACITINIB

RUXOLITINIB





baseline



3 months treatment


4 months treatment

TOFACITINIB


tablets 5-15 mg/ die


Ruxolitinib is a JAK1 and JAK2 Inhibitor

- Potential mechanism of action:
 - Inhibits signaling of cytokine and growth factor receptors that use JAK1 and JAK2 for signaling
 - Suppresses the growth (JAK2 inhibition) of malignant cells
 - Down-regulates the cytokines (JAK1 and JAK2 inhibition) that contribute to hypermetabolic state
- Not selective for JAK2V617F (patients with and without JAK2 mutation benefit)



JAK Inhibitors





Vitiligo in Children: A Better Understanding of the Disease.

Review article

Gianfaldoni S, et al. Open Access Maced J Med Sci. 2018.

Authors

Gianfaldoni S¹, Tchernev G^{2,3}, Wollina U⁴, Lotti J⁵, Satolli F⁶, França K⁷, Rovesti M⁶, Lotti T¹.

Author information

- 1 University G. Marconi of Rome, Dermatology and Venereology, Rome 00192, Italy.
- 2 Medical Institute of the Ministry of Interior, Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
- 3 Onkoderma, Private Clinic for Dermatologic Surgery, Sofia, Bulgaria.
- 4 Städtisches Klinikum Dresden Department of Dermatology and Allergology, Dresden, Sachsen, Germany.
- 5 University G. Marconi of Rome, Dept. of Nuclear, Subnuclear and Radiation Physics, Via Plinio 44, Rome 00193, Italy.
- 6 Department of Dermatology, University of Parma, Via Gramsci 14, Parma, Parma 43126, Italy.
- 7 University of Miami School of Medicine, 1400 NW 10th Avenue, Miami, Florida 33136-1015, United States.

Citation

Open Access Maced J Med Sci. 2018 Jan 20;6(1):181-184. doi: 10.3889/oamjms.2018.040. eCollection 2018 Jan 25.

Abstract

Vitiligo is an important skin disease of childhood. The authors briefly discuss the etiopathobiology, clinics and comorbidities of the disease.

PMID: 29484022 [] PMCID: PMC5816297

Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.

Gianfaldoni S, et al. Open Access Maced J Med Sci. 2018.

Authors

Gianfaldoni S¹, Tchernev G², Wollina U³, Roccia MG⁴, Fioranelli M⁵, Lotti J⁵, Rovesti M⁶, Satolli F⁶, Valle Y⁷, Goren A⁸, Tirant M⁹, Situm M¹⁰, Kovacevic M^{8,10}, França K¹¹, Lotti T⁸.

Author information

- 1 University G. Marconi of Rome Dermatology and Venereology, University G. Marconi of Rome, Rome, Italy.
- 2 Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria.
- 3 Städtisches Klinikum Dresden, Department of Dermatology and Venereology, Dresden, Sachsen, Germany.
- 4 University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India.
- 5 G. Marconi University Department of Nuclear Physics, Subnuclear and Radiation, Rome, Italy.
- 6 Department of Dermatology, University of Parma, Parma, Italy.
- 7 Vitiligo Research Foundation, New York, United States.
- 8 I Iniversity G. Marconi of Rome Dermatology

Abstract


BACKGROUND: Vitiligo is an acquired pigmentary cutaneous disease, characterised by the progressive loss of melanocytes, resulting in hypopigmented skin areas which progressively become amelanotic. Classically, vitiligo treatments are unsatisfactory and challenging. Despite the continuous introduction of new therapies, phototherapy is still the mainstay for vitiligo repigmentation.

AIM: The aim of this multicenter observational retrospective study was to evaluate the efficacy and safety of the nb - UVB micro - phototherapy (BIOSKIN EVOLUTION®), used alone or in associations with an oral Janus kinase inhibitor (Tofacitinib citrate), in the treatment of stable or active forms of localised vitiligo.

MATERIAL AND METHODS: Fifty eight patients had been treated with n-UVB microphotootherapy (Group A); 9 patients had been treated with phototherapy plus Tofacitinb citrate (Group B). RESULTS: Among Group A, 42 patients (72%) obtained a re-pigmentation rate higher than 75%, with a medium value of 77%. 11 patients (19%) achieved a marked improvement of the clinical findings with a repigmentation rate between 50-75%; 4 patients (8%) showed a moderate response with a lesional repigmentation of 25-50%. Only one patient (1%) had a poor response to the phototherapeutic treatment.

CONCLUSION: Nb - UVB micro-focused phototherapy is one of the most effective therapeutic options for vitiligo treatment. The association of micro-focused phototherapy to Tofacitinib citrate seems to provide better clinical results in term of repigmentation rate.

PMID: 29483979 [] PMCID: PMC5816312




Trends in Molecular Medicine

Systemic treatment for Vitiligo 2016 – 2017


- JAK Inhibitors
- EdnrB Wnt Signaling
- CD20 Mab
- Afamelanotide
- Statins
- Minocycline
- Low Dose Cytokines and Growth Factors


EdnrB – Wnt Signaling

- Endothelin receptor type B is a <u>G protein-</u> <u>coupled receptor</u> which activates a phosphatidylinositol-calcium second messenger system.
- Regulation In <u>melanocytic</u> cells the EDNRB gene is regulated by the <u>microphthalmia-</u> <u>associated transcription factor</u>. Mutations in either gene are links to <u>Waardenburg</u> <u>syndrome</u>.




ANGEROUS





Summary of the possible cellular and humoral immune mechanisms of vitiligo Expert Reviews in Molecular Medicine ©2001 Cambridge University Press





Systemic treatment for Vitiligo 2016 – 2018

- JAK Inhibitors
- EdnrB Wnt Signaling
- CD20 Mab
- Afamelanotide
- Statins
- Minocycline
- Low Dose Cytokines and Growth Factors

Unconventional Treatments for Vitiligo: Are They (Un) Satisfactory?

Review article

Gianfaldoni S, et al. Open Access Maced J Med Sci. 2018.

Authors

Gianfaldoni S¹, Tchernev G^{2,3}, Lotti J⁴, Wollina U⁵, Satolli F⁶, Rovesti M⁶, França K⁷, Lotti T¹.

Author information

- 1 University G. Marconi of Rome, Dermatology and Venereology, Rome 00192, Italy.
- 2 Department of Dermatology, Venereology and Dermatologic Surgery, Medical Institute of Ministry of Interior (MVR-Sofia), General Skobelev 79, 1606 Sofia, Bulgaria.
- Onkoderma Policlinic for Dermatology, Venereology and Dermatologic Surgery, General Skobelev 26, 1606, Sofia, Bulgaria.
- 4 University G. Marconi of Rome, Dept. of Nuclear, Subnuclear and Radiation Physics, Via Plinio 44, Rome 00193, Italy.
- 5 Städtisches Klinikum Dresden, Department of Dermatology and Allergology, 01067 Dresden, Germany.
- 6 Department of Dermatology, University of Parma, Via Gramsci 14, Parma, Parma 43126, Italy.
- 7 University of Miami School of Medicine, 1400 NW 10th Avenue, Miami, Florida 33136-1015, United States.

Citation

Open Access Maced J Med Sci. 2018 Jan 21;6(1):170-175. doi: 10.3889/oamjms.2018.038. eCollection 2018 Jan 25.


Abstract

The authors show a brief overview of the vitiligo's unconventional therapies. A part for well-documented effectiveness of L-phenylalanine, PGE2 and antioxidant agents in the treatment of vitiligo, for the other therapeutical approaches more investigations are needed.

PMID: 29484020 [] PN

PMCID: PMC5816295


- B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all <u>B-cells</u> beginning at the pro-B phase (<u>CD45</u>R+, <u>CD117</u>+) and progressively increasing in concentration until maturity.
- In humans CD20 is encoded by the *MS4A1* gene.




Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy.

Lotti T, Hercogova J, Fabrizi G.

Expert Opin Pharmacother. 2015;16(16):2485-96. doi: 10.1517/14656566.2015.1087508









Systemic treatment for Vitiligo 2016 – 2018


- Monoclonal antibody anti CD20
- RITUXIMAB




Rituximab Mechanisms of Action




Golay et al. Blood. 2000;95:3900; Reff et al. Blood. 1994;83:435; Byrd et al. Blood. 2002;99:1038.



Natural killer cells, monocytes





P.N.E.I.: life and death of skin cells. A new paradigm in the treatment of vitiligo: the low dose cytokines therapy.

Rivkina T, Hercogova J, Lotti T.

Dermatol Ther. 2016 Mar-Apr;29(2):134-5. doi: 10.1111/dth.12268.




Systemic treatment for Vitiligo 2016 – 2017

- JAK Inhibitors
- EdnrB Wnt Signaling
- CD20 Mab
- Afamelanotide
- Statins
- Minocycline
- Low Dose Cytokines and Growth Factors

- Afamelanotide (ⁱ/ <u>æfəmε'lænoʊtaɪd/</u> (<u>INN</u>) (brand name Scenesse), also known as melanotan I (or melanotan-1), originally developed at the University of Arizona and now by Clinuvel Pharmaceuticals, is a synthetic peptide and analogue of the naturally occurring melanocortin peptide hormone α -melanocyte stimulating
- <u>hormone</u> (α-MSH).



- It has been shown to induce the production of darkening dermal pigmentation through melanogenesis and thereby subsequently reduce sun (UV) damage to UV light-exposed skin in preliminary research and human clinical trials. Its amino acid sequence is Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, and it is additionally known as [Nle⁴,D-Phe⁷]-α-MSH, which is sometimes abbreviated as **NDP-MSH** or **NDP-\alpha-MSH** (especially in the scientific literature).
- Afamelanotide



 Afamelanotide is the <u>International</u> <u>Nonproprietary Name</u> for the molecule [Nle⁴,D-Phe⁷]α-MSH^[3] initially <u>researched and</u> <u>developed</u> as melanotan-1 <u>i/mɛ'lænoʊtæn/</u> and later, CUV1647 (by Clinuvel)















Afamelanotide













Afamelanotide





Systemic treatment for Vitiligo 2016 – 2017


- JAK Inhibitors
- EdnrB Wnt Signaling
- CD20 Mab
- Afamelanotide

Statins

- Minocycline
- Low Dose Cytokines and Growth Factors

- Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering medications.
- Statins have been found to reduce cardiovascular disease and mortality in those who are at high risk. The evidence is strong that statins are effective for treating CVD in the early stages of a disease (secondary prevention) and in those at elevated risk but without CVD (primary prevention)

 They <u>inhibit</u> the enzyme <u>HMG-CoA reductase</u> which plays a central role in the production of cholesterol. High cholesterol levels have been associated with <u>cardiovascular disease</u> (CVD).



Lipids Health Dis. 2004; 3: 7. Published online 2004 May 10. doi: 10.1186/1476-511X-3-7 PMCID: PMC425594

Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo

Martin Noël,1 Claude Gagné,2 Jean Bergeron,2 Jean Jobin,1 and Paul Poirier



Background

•HMG-CoA reductase inhibitors (statins) are commonly used in medicine to control blood lipid disorder. Large clinical trials have demonstrated that statins greatly reduces cardiovascular-related morbidity and mortality in patients with and without coronary artery disease. Also, the use of HMG-CoA reductase inhibitors has been reported to have immunosuppressive effects.



- Case presentation
- We describe an unusual case of regression of vitiligo in a patient treated with high dose simvastatin. The relation between simvastatin and regression of vitiligo in this case report may be related to the autoimmune pathophysiology of the disease.









Figure 1 Timeline progression of the vitiligo

















Nature Reviews | Neuroscience

STATINS DOSAGE !?





Systemic treatment for Vitiligo 2016 – 2018

- JAK Inhibitors
- EdnrB Wnt Signaling
- CD20 Mab
- Afamelanotide
- Statins
- Minocycline
- Low Dose Cytokines and Growth Factors


Systemic treatment for Vitiligo 2016 – 2018

- Minocycline
- has a wide repertoire of anti inflammatory, immune regulatory and free radicals scavenging effects
- 100mg/die






Minocycline (INN) is a broad-spectrum tetracycline antibiotic, and has a broader spectrum than the other members of the group. It is a <u>bacteriostatic</u> antibiotic, classified as a long-acting type. As a result of its long half-life it generally has serum levels 2–4 times that of the simple watersoluble tetracyclines (150 mg giving 16 times the activity levels compared with 250 mg of tetracycline at 24–48 hours).




- Minocycline is the most lipid-soluble of the tetracycline-class antibiotics, giving it the greatest penetration into the prostate and brain, but also the greatest amount of central nervous system (CNS)related side effects, such as vertigo.
- A common side effect is diarrhea. Uncommon side effects (with prolonged therapy) include skin discolouration and autoimmune disorders that are not seen with other drugs in the class.










Dermatol Ther. 2010 May-Jun;23(3):305-7. **Oral minocycline in the treatment of vitiligo--a preliminary study.** Parsad D1, Kanwar A.



Systemic treatment for Vitiligo 2016 – 2018

- JAK Inhibitors
- EdnrB Wnt Signaling
- CD20 Mab
- Afamelanotide
- Statins
- Minocycline
- Low Dose Cytokines and Growth Factors

- Cytokines (cyto, from <u>Greek</u> "κύτταρο" kyttaro "cell" + kines, from Greek "κίνηση" kinisi "movement") are a broad and loose category of small proteins (~5–20 <u>kDa</u>) that are important in <u>cell signaling</u>.
- Their release has an effect on the behavior of cells around them. It can be said that cytokines are involved in <u>autocrine signalling</u>, <u>paracrine signalling</u> and <u>endocrine signalling</u> as immunomodulating agents.

On pubmed... Torello Lotti and coworkers

Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy.

Review article

Lotti T, et al. Expert Opin Pharmacother. 2015.

Authors

Lotti T¹, Hercogova J², Fabrizi G³.

Author information

- 1 a 1 University of Rome "G.Marconi", Rome, Italy professor@torellolotti.it.
- 2 b 2 Dermatology Clinic Bulovka Dermatology Bulovka Hospital , Prague Czech Republic.
- 3 c 3 University of Parma Clinica Dermatologica , Parma, Italy.

Citation

Expert Opin Pharmacother. 2015;16(16):2485-96. doi: 10.1517/14656566.2015.1087508. Epub 2015 Sep 15.

Abstract

INTRODUCTION: Vitiligo is a skin disorder characterized by a progressive depigmentation, which is caused by the loss of melanocytes at the cutaneous level. A shift of the immune system with a prevalence of T helper (Th)1/Th17 response instead of a Tregs/Th2 one and may be part of etiology of 10 vitiligo.

AREAS COVERED: This review describes the major points of vitiligo onset and shows the cutting-edge results in the field of low-dose medicine in the treatment of dermatologic diseases and, in particular. in vitiligo. In this review on advances in vitiligo pharmacotherapy, the most pertinent recent publications are reported. Electronic databases such as PubMed were searched for terms 'low-dose medicine' or 'low dose and vitiligo' or 'low dose and psoriasis.' -----

EXPERT OPINION: The availability of a systemic treatment for vitiligo, based on the oral administration of low-dose activated signaling molecules represents an opportunity for the dermatologists to overcome some specific pitfalls of currently available therapeutic protocols.

PMID: 26372794 [Indexed for MEDLINE]

On pubmed... Torello Lotti and coworkers

Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin.

Barygina V, et al. J Dermatol Sci. 2015.

Authors

Barygina V¹, Becatti M², Lotti T³, Moretti S⁴, Taddei N⁵, Fiorillo C⁶.


Author information

- 1 Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, viale Morgagni, 50, 50134 Florence, Italy. Electronic address: v.barygina@gmail.com.
- 2 Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, viale Morgagni, 50, 50134 Florence, Italy. Electronic address: matteo.becatti@unifi.it.
- Dermatology and Venereology Division, Guglielmo Marconi University, Via Plinio, 44, 00193 Roma, Italy. Electronic address: professor@torellolotti.it.
- 4 Department of Surgery and Translational Medicine, Division of Dermatology, Viale Michelangelo 41, 50100 Florence, Italy. Electronic address: silvia.moretti@unifi.it.
- 5 Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, viale Morgagni, 50, 50134 Florence, Italy. Electronic address: niccolo.taddei@unifi.it.
- 6 Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence viale Morgagni 50 50134 Florence

Abstract

BACKGROUND: Vitiligo is a systemic dermatological disorder characterized by the loss of skin pigmentation due to melanocyte injury or aberrant functioning. Recent data underline its multifactorial etiology with significant involvement of autoimmune and redox alterations. The major role in vitiligo cellular immunity is displayed by augmented Th1 and Th17 and suppressed TREGs and Th2 lymphocyte populations. Our previous studies indicate a marked redox imbalance in perilesional ("PL", i.e. obtained from visibly unaffected skin surrounding the depigmented area in vitiligo patients) keratinocytes where the massive infiltration of inflammatory cells takes place. No defined therapy exists for vitiligo. Although a number of approaches have been used for the induction of TREGs and Th2 cells. they may be associated with significant offtarget effects.

OBJECTIVE: In order to identify a targeted approach for vitiligo treatment we, first, aimed to investigate the possible source of ROS overproduction in PL keratinocytes. Second, we tested the effect of low-dose selected cytokines,



DERMATOLOGIC THERAPY ISSN 1396-0296

The neuro-immuno-cutaneousendocrine network: relationship between mind and skin

BENEDETTA BRAZZINI,* ILARIA GHERSETICH,* JANA HERCOGOVA,† & TORELLO LOTTI*

*Department of Dermoscience, University of Florence, Florence, Italy, and †Department of Dermatology, Charles University, Prague, Czech Republic






Review

Can the brain inhibit inflammation generated in the skin? The lesson of α -melanocyte-stimulating hormone

Torello Lotti, MD, Beatrice Bianchi, PhD, Ilaria Ghersetich, MD, Benedetta Brazzini, MD, and Jana Hercogova, MD






Lotti T et al. International Journal of Dermatology 2002, 41, 311–318

Figure 1 In the brain α -melanocyte stimulating hormone is synthetized predominantly in the pituitary gland. When administered into the cerebral ventriculi (in mice) *a*-MSH inhibits the cutaneous inflammation induced by application of topical irritants and intradermal injection of cytokines. This action is related to the integrity of the spinal cord descending neurogenic pathways and of β_2 receptors in the periphery. a-melanocyte stimulating hormone is also released in the plasma by the pituitary gland and by different cells, including keratinocytes, melanocytes, monocytes, macrophages, endothelial cells, adipocytes, fibroblasts and mast cells. Membrane receptors for α -MSH are present both in the brain and on nearly all the cells that produce and release α-MSH and participate in cutaneous inflammation mainly by reducing and terminating the same flogistic reactions

Autoimmune markers in vitiligo patients appear correlated with obsession and phobia

S. Moretti,[†] M. Arunachalam,^{†,*} R. Colucci,[†] S. Pallanti,[‡] J.A. Kline,[§] S. Berti,[†] F. Lotti,[†] T. Lotti[†]

[†]Department of Critical Care Medicine and Surgery, Division of Dermatology, University of Florence, Florence, Italy [‡]Department of Psychiatry, University of Florence, Florence, Italy [§]Department of Emergency Medicine Research, Carolinas Medical Center, Charlotte, NC, USA




(habitual "normal" for


that person)

(habitual "normal" for

that person)

shown in the graph are significantly higher in autoimmune markers vs. negative autoimmune markers vitiligo patients.





Version 26.7 (Spring 2011 Edition)



Vitiligo: successful combination treatment based on oral low dose cytokines and different topical treatments.

Lotti T, et al. J Biol Regul Homeost Agents. 2015 Jan-Mar.

Authors Lotti T¹, Hercogova J², Wollina U³, Chokoeva AA⁴, Zarrab Z⁵, Gianfaldoni S⁶, Roccia MG⁷, Fioranelli M⁸, Tchernev G⁴.

Abstract

The current treatments for Vitiligo are not completely satisfactory in terms of clinical, aesthetic and compliance results for patients. Recently, combination therapies had been introduced with positive results. In this paper the combination between systemic oral treatment with Low Dose Cytokines in association with other topical treatments was evaluated. Positive results were obtained both with Low Dose Cytokines alone or in association with microphototherapy with positive percentage of skin repigmentation varying between 74% and 90%. Collected data allow the authors to affirm that the treatment with <u>oral low dose SKA drugs is efficacious per se and highly</u> efficacious in association with targeted phototherapy.



Novel topical cream delivers safe and effective sunlight therapy for vitiligo by selectively filtering damaging ultraviolet radiation.

<u>Goren A¹</u>, <u>Salafia A</u>, <u>McCoy J</u>, <u>Keene</u> <u>S</u>, <u>Lotti T</u>.

Dermatol Ther. 2014 Jul-Aug;27(4):195-7.

In vitro evaluation of a novel topical cream for vitiligo and psoriasis that selectively delivers NB-UVB therapy when exposed to sunlight.

McCoy J¹, Goren A, Lotti T.

Dermatol Ther. 2014 Mar-Apr;27(2):117-20.



Excimer Light





Bioskin Evolution



Excimer Lasers





<text><section-header><section-header><section-header><section-header><section-header><text><text><text><text><text>

is a commonly presented treatment for patients of vitiligo and portisis (1.2.). Net UVB photoet therapy has gained prevalence over psoralen plus ultraviolet. And broadband UVB therapies because it has similar efficacy with fower side effects (1.3.4). Unfortunately patient compliances is a major obstacle in the effective clinical application of NI UVB photoherapy (5.6). The majority of require toos to three visits per visck for a long too the second second

UVA-1 355 nm Alba Laser -





Thank you for your attention